Going Beyond Antibiotics! Developing First-In-Class

New Post Public Reply Private Reply Replies (0) Message Board
crookedneck

Going Beyond Antibiotics! ™

Developing First-In-Class Anti-Infectives 
to Fight Bacteria, Viruses and Fungi

Corporate Profile

ANTI-INFECTIVE COMPOUNDS EFFECTIVE AGAINST BACTERIA, VIRUSES AND FUNGI

NovaBay Pharmaceuticals is a clinical-stage biotechnology company focused on developing its proprietary and patented Aganocide® compounds.  Aganocides are novel, broad-spectrum, fast-acting, synthetic anti-infectives designed to mimic the body’s defense against infection.  They are active against bacteria, fungi and viruses, and are being developed to treat and prevent a wide range of local, non-systemic infections with a low likelihood of developing bacterial resistance.
  
NOVABAY’S FOUR BUSINESS UNITS

NovaBay is focusing its technology on four distinct therapeutic areas:  dermatology, ophthalmology, urology and hospital infections.  In dermatology, the focus is on developing NVC-422 gel for impetigo and acne.  NovaBay has the advantage of being partnered with Galderma, the leading dermatology company in the world.  In ophthalmology, the company anticipates continuing its development of NVC-422 for the treatment of adenoviral conjunctivitis to confirm the encouraging results shown for epidemic keratoconjunctivitis (EKC) seen in the adenoviral conjunctivitis trial. In urology, NovaBay aims to reduce the incidence of urinary catheter blockage and encrustation (UCBE) and the associated urinary tract infections with an irrigation solution containing NVC-422.  In hospital infection, NovaBay is targeting the six-million-patient market of chronic non-healing wounds, such as pressure, venous stasis and diabetic ulcers with its proprietary antimicrobial solution, NeutroPhase®, which has received two 510(k) clearances from the Food and Drug Administration.

COLLABORATION WITH GALDERMA

NovaBay has entered into and recently expanded an agreement with Galderma S.A. to develop and commercialize Aganocide compounds in acne, impetigo and other dermatological indications. 

News and Features  

February 9, 2012
NovaBay Pharmaceuticals Provides Business Update and 2012 Outlook

Archive of Conference Call
 Click Here To Listen

February 8, 2012
NovaBay Pharmaceuticals to Present at the 14th Annual BIO CEO & Investor Conference

February 7, 2012
NovaBay Pharmaceuticals to Hold Conference Call to Provide Year-end Business Update and 2012 Outlook

January 23, 2012
NovaBay Prepares to Launch Global Phase 2b Ophthalmic Study of NVC-422

January 9, 2012
NovaBay Pharmaceuticals Announces Strategic Marketing Agreement for NeutroPhase in China

November 30, 2011
NovaBay Establishes Primary Proof of Concept for NVC-422 Phase 2 UCBE Clinical Program

November 14, 2011
NovaBay Pharmaceuticals' Aganocide Compound, NVC-422, Featured in Drugs of the Future

November 7, 2011
NovaBay Pharmaceuticals Reports Third Quarter Financial Results

October 14, 2011
NovaBay Pharmaceuticals Spotlights NeutroPhase at the Symposium on Advanced Wound Care (SAWC)

October 14, 2011
NovaBay Pharmaceuticals Spotlights NeutroPhase at the Symposium on Advanced Wound Care (SAWC)

October 4, 2011
NovaBay Pharmaceuticals Names David W. Stroman, Ph.D. As Head of Ophthalmic Drug Development

September 28, 2011
NovaBay Pharmaceuticals Names Russell A. Hoon As Vice President of its Advanced Wound Care Business Unit

September 21, 2011
NovaBay Pharmaceuticals to Present at the LD MICRO Invitational Conference

September 12, 2011
NovaBay Pharmaceuticals Reports Positive Results in Sinus Infection Study

August 25, 2011
NovaBay Pharmaceuticals Highlighted in Cataract & Refractive Surgery Today

August 24, 2011
NovaBay Pharmaceuticals to Present at The 2011 Southern California Investor Conference

August 10, 2011
NovaBay Pharmaceuticals Reports Second Quarter Financial Results

July 11, 2011
NovaBay Pharmaceuticals Provides Business Update

July 5, 2011
NovaBay Pharmaceuticals Announces the Closing of its $5.2 Million Registered Direct Offering of Common Stock and Warrants

June, 29 2011
NovaBay Pharmaceuticals, Inc. Announces Pricing of a $5.2 Million Registered Direct Offering of Common Stock and Warrants

June, 16, 2011
NovaBay Regains Worldwide Rights to Its Aganocide Compounds from Alcon

May 23, 2011
NovaBay Pharmaceuticals to Present at the 7th Annual Spring Growth Stock Conference Hosted by Security Research Associates, Inc. on May 24

May 18, 2011
Archive of Conference call Re: Results from Phase 2 Clinical Study for the Treatment of Adenoviral Conjunctivitis
 Click Here To Listen

May 18, 2011
NovaBay Pharmaceuticals Reports Results from Phase 2 Clinical Trial of NVC-422 for Adenoviral Conjunctivitis

May 16, 2011
NovaBay Pharmaceuticals, Inc. Reports First Quarter Financial Results

May 6, 2011
NovaBay Pharmaceuticals Spotlights Three New Aganocide Compounds with Confirmed Activity against Ophthalmic Pathogens

April 19, 2011
NovaBay Pharmaceuticals Spotlights Positive Results From NeutroPhase Study of 26 Patients With Chronic Non-Healing Wounds

April 14, 2011
NovaBay Pharmaceuticals Awarded 1st Place for Outstanding Scientific Presentation at The Simon Foundation for Continence Conference

April 12, 2011
NovaBay Pharmaceuticals Spotlights Positive Results for Its Novel Anti-Infective at 2011 Simon Foundation for Continence Conference

March 28, 2011
Archive of Conference call Re: Business and Clinical Developments from NovaBay's Four Business Units
 Click Here To Listen

March 10, 2011
NovaBay Pharmaceuticals Provides Fourth Quarter and Full Year 2010 Financial Results and Business Unit Updates

March 9, 2011
NovaBay Pharmaceuticals to Present at the Roth Capital 23rd Annual Growth Stock Conference on March 16

March 2, 2011
NovaBay Pharmaceuticals Initiates Phase 2 Clinical Trial for the Treatment of Urinary Catheter Blockage and Encrustation

February 18, 2011
NovaBay Pharmaceuticals Ranked No. 7 in Biotech Industry in Fast Company's Annual List of World's Most Innovative Companies

February 8, 2011
NovaBay Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference

February 2, 2011
NovaBay Pharmaceuticals Provides Summary of 2010 Accomplishments and 2011 Outlook

January 7, 2011
NovaBay Pharmaceuticals to Present at 2011 Biotech Showcase Conference

January 6, 2011
NovaBay Pharmaceuticals Reports Activity of Aganocide NVC-422 Against Deadly "Superbug" producing NDM-1 (New Delhi Metallo-beta-lactamase-1)

December 16, 2010
NovaBay Pharmaceuticals CEO Contributes Article to The Scientist

December 6, 2010
NovaBay Pharmaceuticals and Galderma Expand Their Agreement to Include Impetigo

Novabay Pharmaceuticals (NBY) Stock Research Links

NBY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Major Donations Boost Mesothelioma Research Funding

Updated Category News Views 126

Significant Boosts in Mesothelioma Support November's chill didn't slow down major support for mesothelioma initiatives. On October 22, 2026, during the grand setting of the Foundation's 2026 International Symposium on Malignant Mesothelioma in The Woodlands, Texas, MesoCare.org and Danziger & De Llano, LLP stepped up big time. Their philanthropic moves weren't just about...

Continue Reading
Andersen's Window Revamp: Addressing Demand Surge

Updated Category News Views 53

Portfolio Boost: Adapting to Market Needs If you're sniffing around the windows business, there's a fresh breeze of innovation blowing from Andersen. They're not just sitting around drumming their fingers—they're rolling up their sleeves and fine-tuning their offerings. With half of homeowners swinging a hammer on renovations last year, the company sees an opportunity...

Continue Reading
ASUR's October Traffic Sees Mixed Results Across Regions

Updated Category News Views 77

A Patchwork of Gains and Losses Take a look at Grupo Aeroportuario del Sureste, S.A.B. de C.V. (NYSE: ASR), and you’ll see a mixed bag when it comes to October 2026’s passenger traffic. While some regions like Puerto Rico and Colombia took a step forward, others like Mexico and Costa Rica tripped up, resulting in an overall decline of 0.9% compared to last October....

Continue Reading
Tata Power Faces Enforcement Order for $650M Debt

Updated Category News Views 98

Tata's Troubles Escalate Grab a cup of coffee, folks, because this is one rollercoaster of a story that every investor needs to have on their radar. We're talking about Singapore courts coming down on Tata Power like a freight train, with enforcement orders that feel like a page out of a high-stakes drama. The Gavel Drops: What's Happening? The court in Singapore has...

Continue Reading
Silvercorp Navigates Q2 with Strategic Resilience

Updated Category News Views 113

Silvercorp's Q2: A Mixed Bag of Gains and Strains Coming in hot this November, Silvercorp swings between highs and lows for Q2 Fiscal 2027. They reported a not-too-shabby adjusted net income of $18.4 million—or $0.08 a pop per share. No one's throwing a parade for that, but it's stable sailing amidst some choppy waters. Safety Comes with a Price Safety upgrades have...

Continue Reading
2026 Midterms: Bond Market Shifts Investors Eye

Updated Category News Views 54

Reassessing Bonds Post-2026 Midterms When the election circus packs up its tents, investors like us are left standing in the wreckage, trying to figure out what's next for our portfolios. That's just where One Oak Capital Management's latest research fits into our jigsaw—exploring how the political winds can ripple through the layers of the bond market. Federal...

Continue Reading
WIC 2026: Global Connectivity and Cyber Futures

Updated Category News Views 117

Connectivity Takes Center Stage in Wuzhen When you throw 1,800 movers and shakers into a room focused on the future of the internet, sparks are gonna fly. That's exactly what's going down at the 2026 World Internet Conference in Wuzhen, China. Brass tacks: this ain't just another snooze-fest. The theme this year screams significance—'Open Source and Openness, Joined...

Continue Reading
Alley Cat Allies Sues Lincolnton Over Cat Shooting

Updated Category News Views 354

Legal Battle Over a Cat's Tragic End Picture the scene: a peaceful neighborhood in Lincolnton, Georgia, where the serenity was ripped apart by the shocking shooting of Piper the cat. This isn't some playground scuffle, my friends. Alley Cat Allies has taken this tragedy to the courts, filing a lawsuit against the city and its mayor. What's at stake here isn't just legal...

Continue Reading
TELUS Boosts Board with Strategic Executive Appointments

Updated Category News Views 69

New Faces on the TELUS Board: Shaping the Future Alright, investors, here's the scoop straight from the trenches: TELUS (TSX:TU) is shaking things up at the top. Marc Allera and Bill Thomas are stepping into the fray as the newest members of the board, effective January 1, 2027. If you're not familiar with these names, it's time to tune in because they've got the chops to...

Continue Reading
Ravens & MedStar Host Cancer Patients' Tailgate Bash

Updated Category News Views 45

If you thought a hospital could never host a touchdown of a tailgate, think again. The Baltimore Ravens and MedStar Health joined forces to throw the second annual Ravens Crucial Catch Tailgate Experience. This ain't your average pre-game party, folks—it's a blowout right in the hospital for cancer patients and their families, serving up a hefty dose of fun, food, and,...

Continue Reading

Top 5 Most Recently Viewed Articles

SelectQuote, Inc. Announces Impressive Q2 Fiscal Results

Updated Category News Views 117

Record Quarter for SelectQuote, Inc. SelectQuote, Inc. (NYSE: SLQT) reported significant growth in its consolidated revenue for the second quarter of fiscal year 2025, reaching $481.1 million. This reflects a notable increase from $405.4 million in the same quarter of the prior year. Alongside revenue growth, the company achieved consolidated net income of $53.2 million,...

Continue Reading
Usbit Trading Center Unveils New Logo in Celebration of Growth

Updated Category News Views 137

Usbit Trading Center Celebrates Brand Evolution Usbit Trading Center has officially launched its new logo and visual identity, commemorating a significant milestone in its journey as a global digital asset trading platform. This thoughtful rebranding effort reinforces the company's core values of security, innovation, and accessibility, which are essential in a time when...

Continue Reading
Empowering Biotech Founders with Ignite Golden Tickets Initiative

Updated Category News Views 123

Empowering Biotech Founders with Ignite Golden Tickets Initiative $250,000 of Ignite Golden Tickets will provide opportunities for early-stage biotech founders to leverage LabCentral's lab space, shared resources, and community. LabCentral, a leading network of coworking labs designed to accelerate high-potential biotech startups, has launched its fifth annual Ignite...

Continue Reading
Bitcoin Sees Decline Amid Market Adjustments

Updated Category News Views 48

Bitcoin Pulls Back Bitcoin has seen a decline, falling below $63,000 as traders took profits following a recent rally. The cryptocurrency market is under pressure as investors adjust their positions after the price surge over the weekend. According to data from CoinGecko, Bitcoin dropped by 1.4% in just 24 hours. Other major cryptocurrencies, including ether, BNB from BNB...

Continue Reading
Silver Shines Brightly as Investment Opportunities Expand

Updated Category News Views 156

Silver's Surprising Rise in 2025 The financial landscape is witnessing a remarkable shift as the relentless rise of silver eclipses even gold and the S&P 500 in recent times. Traditionally seen as the overlooked sibling of precious metals, silver is undergoing a transformation that is catching the attention of investors everywhere. With an impressive rise of around 95%...

Continue Reading